The accompanying table presents the top five rated companies with market caps of at least $250 million (USD) from each of the nine new healthcare indexes developed by ETF Innovators [ETFI] from a database of about 400 companies worldwide. The ETFI Global Healthcare Sector PerformIdex consists of 45 top rated companies ranging from small-caps to mega-caps from the following underlying healthcare indexes:
Teva Pharma (TEVA) posted 3Q08 results this morning which beat consensus profit estimates by a penny at 72 cents per share on an adjusted basis with record sales coming in slightly below estimates at $2.84B versus $2.9B expected. Revenue increased by 20% while GAAP net income of $637M rose by 21% from the year-ago period. Results were driven by the proprietary multiple sclerosis drug Copaxone, which posted sales of $562M, representing a 28% increase from the year-ago period. Cash flow from operations more than dou
The accompanying table presents my 60 defensive growth stock picks at the recently launched online investing site Inner8.com , which I wrote about yesterday. My picks are focused on healthcare and consumer staples, along with some cash rich tech companies such as Microsoft (MSFT). My picks include companies across the entire spectrum of market cap and risk in the biotech industry, ranging from top performers such as Amgen (AMGN) and Celgene (CELG) to small and micro-cap picks such as Discovery Labs (DSCO),
The accompanying table presents an updated version of the ETFI Highly Defensive PerformIdex, which is expanded to 40 companies with market caps of at least $10B from the industry groups listed below. This defensive growth index is heavily weighted in consumer staples and healthcare and is now structured to include companies based in Europe, in addition to the United States and Canada.
Compared to the previous version, this index has a lower beta and higher average market cap and adds European companie
I am the Global Editor at MoneyShow.com and each week I interview an investing expert. This week, I spoke with Allan Nichols, editor of Morningstar InternationalInvestor, who identifies the pitfalls and opportunities in global market today.
Q. Allan, how can investors protect themselves should the financial crisis in the US result in prolonged bear markets around the world?
A. Studies have shown the majority of returns from the stock market have been concentrated over a relatively f
According to a SEC 8-K filing today, an amendment has been submitted to the FDA for Momenta Pharma's (MNTA) Enoxaparin Sodium Injection Abbreviated New Drug Application [ANDA] by its partner, Sandoz, which is the generic drug operating division of Novartis (NVS). Momenta believes the amendment represents a complete response to the agency's concerns over the potential for immune-mediated reactions to the product, which is intended to be a generic equivalent of the injectable blood thinner Lovenox.
In mid-July, Novartis (NVS) reported better-than-expected financial results for Q208 due to sales growth of 14% (which included a 9% forex benefit thanks to a weak US Dollar), resulting in an EPS of $0.98 for the quarter. Pharmaceutical sales were driven by strong demand for the blood pressure drug Diovan, which faces generic competition in 2012, and cancer drugs such as Gleevac, Zometa, and Femara. Novartis is expected to file for regulatory approval of cancer drug Afinitor by the end of this year. As illustrated in the accompanying five-year chart, Novartis has outperformed bo
Analysts' Recommendation: Buy 30 Days Ago: Buy Analysts' Target: $49 Analysts' Targets HSBC Securities $49 Add Thursday, June 12, 2008 BusinessWeek Rankings Best Global Brands Best Global Brands 2006 #43 2005 #43 Novartis AG provides healthcare solutions that address the needs of patients and societies worldwide. Its Pharmaceuticals division researches, develops, manufactures, distributes, and sells pharmaceuticals in therapeutic areas, including cardiovascular and metabolism; oncology and hematology; neuroscience; respiratory; infectious diseases, tra...
"The pipelines of most Big Pharmas are bone dry; last year, the FDA approved the lowest number of new drugs (19) since 1983," notes Louis Basenese, contributing editor to the industry-leading The Oxford Club.
"But opportunity always lurks in the wreckage, and one Big Pharma, in particular, is being unfairly punished." Here's his bullish outlook on Novartis (NYSE: NVS), which he calls the "only Big Pharma worth owning."
"Unlike others in the sector, Novartis doesn't suffer from an empty pipeline. It's launched more drugs globally than any other firm in the past seven years. It has more than 10
In my opinion, global large-cap pharmacueticial stocks, including Pfizer , Novartis , Astrazenca , GlaxoSmithKline , Wyeth and Eli Lilly are currently substantially undervalued. These companies are currently paying out huge dividends and trading at sensible P/Es. Unlike their small-cap high-risk research counterparts, these blue-chip stocks represent strong, yet low risk growth. Why risk your money on an obscure new cure for bird-flu, from a dodgy one-man company, when you don't have to?
While sales of their products may be slowing in the OECD developed world, ...
Buy Report: Novartis AG ADR (NYSE: NVS) prepared 20060417
Key Stats:
Last Close: $55.81
Market Cap $Mil: 130,368
Sales $Mil: 35,526
About Novartis:
- Latin for “New Arts,� Novartis is a Switzerland-based manufacturer of pharmaceutical, health-care, and vision products. The firm was formed in 1996 by the merger of Ciba-Geigy and Sandoz. Areas of specialty in branded drugs include oncology and cardiovascular products. Consumer health-care brands include such familiar names as Ex-Lax, Maalox, Lamisil, and Gerber. Its Ceiba-Geigy division makes disposable contact lenses as well as heal...
Data powered by QuoteMedia.
All Rights Reserved.
Data delayed 15 to 20 minutes unless otherwise indicated.
Terms of Use.
None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.
NVS
About Novartis AG
- Answers.com
I am the Global Editor at 
"The pipelines of most Big Pharmas are bone dry; last year, the FDA approved the lowest number of new drugs (19) since 1983," notes 
